Reshma Kewalramani, Vertex CEO (BIO via YouTube)

Ver­tex strikes out on its lat­est big shot at a rare ge­net­ic dis­ease. But they're go­ing to keep on swing­ing

It’s been sev­er­al months since Ver­tex culled one of its small mol­e­cules for al­pha-1 an­tit­rypsin de­fi­cien­cy (AATD), tak­ing a big hit af­ter ev­i­dence of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.